Nature Search

Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies

Specific biological markers that reliably predict unfavorable outcome during first-line treatment for patients with Hodgkin lymphoma are lacking. Recent analyses have shown that differences in hematotoxicity exist among male and female Hodgkin lymphoma patients, with a better prognosis observed in female patients. Klimm and Engert discuss the reasons for these differences in hematotoxicity and how these differences relate to patient outcome.

Beate Klimm
Andreas Engert
Reviews06 May 2008
Nature Clinical Practice Oncology

Volume: 5, P: 316-323
Hodgkin lymphoma—absence of evidence not evidence of absence!

The optimal treatment for patients with advanced-stage Hodgkin lymphoma is an ongoing controversy. A recent trial seemed to answer some of the important open questions in the field; however, closer examination of the data indicates that the answers are not as clear as they might initially seem.

Peter Borchmann
Andreas Engert
Volker Diehl
News & Views04 Oct 2011
Nature Reviews Clinical Oncology

Volume: 8, P: 636-637
Transcriptional reprogramming by mutated IRF4 in lymphoma

Cancer is often associated with mutant transcription factors (TFs) but their functional characterization is challenging. Here, the authors describe a recurrent mutation within TF IRF4 in human lymphomas and they show how it causes a complex switch in TF specificity and functionality.

Nikolai Schleussner
Pierre Cauchy
Stephan Mathas
ResearchOpen Access07 Nov 2023
Nature Communications

Volume: 14, P: 1-18
Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?

Volker Diehl
Andreas Engert
Editorial01 May 2006
Nature Clinical Practice Oncology

Volume: 3, P: 227
Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Osteosarcomas are a heterogenous group of tumours and little is known about how these tumours evolve. Here, Kovac et al. use exome sequencing and discover that although no driver gene explains the majority of these tumours, they are characterized by specific mutation signatures and genomic instability typical of BRCA1/2-deficient tumours.

Michal Kovac
Claudia Blattmann
Daniel Baumhoer
ResearchOpen Access03 Dec 2015
Nature Communications

Volume: 6, P: 1-9
Axillary swelling and a reduced general condition in a middle-aged man

A 48-year-old man presented to his GP with an indolent swelling in his left axillary region. He had also increasingly suffered from night-time sweating and fever. Physical examination and an ultrasound revealed an enlarged lymph node in the left axillary region. The patient was diagnosed with Hodgkin's lymphoma and treated with chemotherapy and involved-field radiotherapy.

Beate Klimm
Andreas Engert
Volker Diehl
Reviews01 Nov 2004
Nature Clinical Practice Oncology

Volume: 1, P: 51-54
Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma

Nodular lymphocyte-predominant Hodgkin lymphoma with IgD+ lymphocyte-predominant (LP) cells is a rare clinical distinct lymphoma subset of B-cell origin. Here the authors show that antigens expressed by Moraxella catarrhalis are recognized by B cell receptors of IgD+ LP cells, suggesting the contribution of chronic antigen stimulation to lymphomagenesis.

Lorenz Thurner
Sylvia Hartmann
Michael Pfreundschuh
ResearchOpen Access18 May 2020
Nature Communications

Volume: 11, P: 1-12
Cancer-related anemia and recombinant human erythropoietin—an updated overview

Anemia can be a debilitating problem that negatively influences overall quality of life, and it can worsen the prognosis for cancer patients. The requirement for red-blood cell transfusions is reduced in patients receiving erythropoietin therapy. This review discusses quality of life issues, the thromboembolic complications associated with erythropoietin treatment, and provides a critical appraisal of the clinical trial data and evidence-based guidelines for erythropoietin treatment.

Julia Bohlius
Olaf Weingart
Andreas Engert
Reviews01 Mar 2006
Nature Clinical Practice Oncology

Volume: 3, P: 152-164
Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin’s lymphoma

Hodgkin’s lymphoma has a genetic component that is poorly understood. In this study, Frampton et al. perform a genome-wide association study in German patients and combine the results with a previously published UK genome-wide association study to identify susceptibility loci at 3p24.1 and 6q23.3.

Matthew Frampton
Miguel Inacio da Silva Filho
Richard S. Houlston
Research22 Oct 2013
Nature Communications

Volume: 4, P: 1-7
Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude

Sven Borchmann
Horst Müller
Andreas Engert
ResearchOpen Access02 Nov 2017
Scientific Reports

Volume: 7, P: 1-8
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility

Classical Hodgkin lymphoma is a cancer that originates in lymph nodes. Little is known about its genetic susceptibility. Here, the authors combined existing and new genome-wide association studies to identify risk loci for classical Hodgkin lymphoma at 6q22.33, and nodular sclerosis Hodgkin lymphoma at 3q28, 6q23.3, 10p14, 13q34, 16p13.13.

Amit Sud
Hauke Thomsen
Richard S. Houlston
ResearchOpen Access01 Dec 2017
Nature Communications

Volume: 8, P: 1-11
State of the art in the treatment of Hodgkin lymphoma

Hodgkin lymphoma has become one of the most successfully treatable cancers; nevertheless, adverse treatment-related side effects still occur. In this Review, Borchmann et al. discuss the current choices for patients with Hodgkin lymphoma by finding the balance between optimal disease control and the risk of long-term sequelae.

Peter Borchmann
Dennis A. Eichenauer
Andreas Engert
Reviews12 Jun 2012
Nature Reviews Clinical Oncology

Volume: 9, P: 450-459
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility

Amit Sud
Hauke Thomsen
Richard S. Houlston
Amendments and CorrectionsOpen Access08 Jan 2019
Nature Communications

Volume: 10, P: 1-3
Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

The Myocardial Infarction Genetics Consortium reports results of a genome-wide association study of early-onset myocardial infarction. The study analyzed common SNPs, common CNVs and rare CNVs and identified SNP alleles at three new loci associated with disease risk.

Sekar Kathiresan
Benjamin F Voight
David Altshuler
Research08 Feb 2009
Nature Genetics

Volume: 41, P: 334-341
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Michael Fuchs
Anne Sophie Jacob
Dennis A. Eichenauer
ResearchOpen Access16 Oct 2023
Leukemia

Volume: 38, P: 160-167
Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Ron D. Jachimowicz
Wolfram Klapper
Andreas Rosenwald
ResearchOpen Access10 Jun 2021
Leukemia

Volume: 35, P: 3589-3593
Epigallocatechin gallate (EGCG) reduces the intensity of pancreatic amyloid fibrils in human islet amyloid polypeptide (hIAPP) transgenic mice

Andras Franko
Diana C. Rodriguez Camargo
Martin Hrabě de Angelis
ResearchOpen Access18 Jan 2018
Scientific Reports

Volume: 8, P: 1-12
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

Sven Borchmann
Horst Müller
Andreas Engert
Research21 Aug 2018
Leukemia

Volume: 33, P: 439-446
Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

Dennis A. Eichenauer
Annette Plütschow
Andreas Engert
Research21 Oct 2019
Leukemia

Volume: 34, P: 953-956
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

Heribert Schunkert and colleagues report a meta-analysis of 14 genome-wide association studies of coronary disease (CAD) followed by replication in additional cohorts. They confirm 10 previously associated loci and identify 13 loci newly associated with CAD.

Heribert Schunkert
Inke R König
Nilesh J Samani
Research06 Mar 2011
Nature Genetics

Volume: 43, P: 333-338
Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

Carla Damaschin
Helen Goergen
Dennis A. Eichenauer
ResearchOpen Access18 Aug 2021
Leukemia

Volume: 36, P: 580-582
A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Richard Houlston and colleagues report results of a genome-wide association study of Hodgkin's lymphoma. They identify three new susceptibility loci at 2p16 (REL), 8q24 and 10p14 (GATA3) and confirm a strong role for the HLA region in disease etiology.

Victor Enciso-Mora
Peter Broderick
Richard S Houlston
Research31 Oct 2010
Nature Genetics

Volume: 42, P: 1126-1130
Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Maria A. Garcia-Marquez
Martin Thelen
Hans A. Schlößer
ResearchOpen Access28 Sept 2021
Leukemia

Volume: 36, P: 760-771
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Paul J. Bröckelmann
Horst Müller
Bastian von Tresckow
ResearchOpen Access09 Oct 2021
Leukemia

Volume: 36, P: 772-780
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci

Philip J. Law
Amit Sud
Richard S. Houlston
ResearchOpen Access23 Jan 2017
Scientific Reports

Volume: 7, P: 1-11
Heritability estimates on Hodgkin’s lymphoma: a genomic- versus population-based approach

Hauke Thomsen
Miguel Inacio da Silva Filho
Kari Hemminki
Research17 Sept 2014
European Journal of Human Genetics

Volume: 23, P: 824-830
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Jingjing Liu
Wendy J. C. Prager - van der Smissen
Antoinette Hollestelle
ResearchOpen Access16 Jun 2020
Scientific Reports

Volume: 10, P: 1-14
Genome-wide association study of germline variants and breast cancer-specific mortality

Maria Escala-Garcia
Qi Guo
Marjanka K. Schmidt
ResearchOpen Access21 Feb 2019
British Journal of Cancer

Volume: 120, P: 647-657

Search

Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies

Hodgkin lymphoma—absence of evidence not evidence of absence!

Transcriptional reprogramming by mutated IRF4 in lymphoma

Will it be another 20 years before Hodgkin lymphoma patients benefit from BEACOPP therapy?

Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency

Axillary swelling and a reduced general condition in a middle-aged man

Lymphocyte predominant cells detect Moraxella catarrhalis-derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma

Cancer-related anemia and recombinant human erythropoietin—an updated overview

Variation at 3p24.1 and 6q23.3 influences the risk of Hodgkin’s lymphoma

Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude

Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility

State of the art in the treatment of Hodgkin lymphoma

Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma

Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

Epigallocatechin gallate (EGCG) reduces the intensity of pancreatic amyloid fibrils in human islet amyloid polypeptide (hIAPP) transgenic mice

Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)

Rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: long-term follow-up of a phase 2 study from the German Hodgkin Study Group

Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

A genome-wide association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21 and 10p14 (GATA3)

Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma

Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis

Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci

Heritability estimates on Hodgkin’s lymphoma: a genomic- versus population-based approach

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Genome-wide association study of germline variants and breast cancer-specific mortality

Search

Quick links

Search

Filter By:

Search

Quick links